The FDA approved Novartis’ Entresto (sacubitril/valsartan) to treat symptomatic heart failure with systemic left ventricular systolic dysfunction in patients aged one year or older.

The twice-daily prescription is currently approved to reduce the risk of cardiovascular death and heart failure hospitalization in individuals with certain types of chronic heart failure. It is usually administered either in conjunction with or in place of other therapies.

The FDA granted the approval based on positive results from a clinical trial in pediatric patients between ages one and 18 years.